Month: September 2021

A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extracts A leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical researchTORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) announce the signing of a Joint Venture agreement (the “JV”) “Pure Psyence” for the development of nature-derived psilocybin extracts and advanced psilocybin formulations for the long-term treatment of psychological trauma and its mental health consequences. Pure Psyence will leverage Psyence’s supply of high-quality standardized psilocybin mushrooms with Pure Extract’s expertise in extraction...

– “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne’s DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading Experts in Both Disease Areas – WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) —  Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, will host a virtual Research and Development Day on Wednesday, October 13, 2021 from 8:00 – 10:30 a.m. ET. “The Muscle to Move to the Clinic” event will focus on Dyne’s co-lead development programs for rare muscle diseases, myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The program will feature presentations, discussion and Q&A with the...

DENVER and VANCOUVER, British Columbia, Sept. 28, 2021 (GLOBE NEWSWIRE) — SPOTLITE360 IOT SOLUTIONS, INC. (“SpotLite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) is pleased to provide a corporate update with regard to its milestones achieved in the course of Q3 2021. On June 15, 2021, the Company’s common shares began trading on the Canadian Securities Exchange and promptly thereafter began initiatives focused on select industries for launching the SpotLite360 software-as-a-service (“SaaS”) solution (the “SpotLite360 Technologies”). As supply chains around the globe continue to evolve in ways that can benefit from blockchain and Internet-of-Things (“IoT”) solutions such as the SpotLite360 Technologies, the Company is strategically positioning itself to align with some of the world’s largest and most complex industries...

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 12th, 2021 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fourth annual Cytokinetics Communications Fellowship Grant program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure, hypertrophic cardiomyopathy (HCM), or spinal muscular atrophy (SMA) communities, and is intended to support increased capacity in communications and outreach. “We are proud to continue our Communications Fellowship Grant program in the coming year as further evidence...

MONTREAL, Sept. 28, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (Nasdaq: VMAR) (“Vision Marine” or the “Company”), the global leader in the electric recreational boating industry serving both OEMs and consumers, today announced it will showcase its E-Motion™ 180hp fully electric powertrain on a Starcraft EX 22 foot pontoon boat at IBEX 2021, taking place September 28th to September 30th in Tampa, Florida. “Pontoon boats offer an ‘all-in-one experience,’ for fishing, cruising, and all types of watersports. The versatility, combined with improved performance specs, is rising in popularity in this ever-growing segment of the recreational boating market,” said Alexandre Mongeon, CEO of Vision Marine Technologies. Pontoon boats represent approximately 20% of the recreational boating market, with sales of pontoon...

HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payment is part of a non-dilutive grant that was originally awarded in 2016 to support Salarius’ operations and development of its lead drug candidate, seclidemstat. Seclidemstat (SP-2577) is a novel, oral tablet, reversible inhibitor of lysine-specific histone demethylase 1 (LSD1), an enzyme that plays a key role in the development and progression of several cancers. This latest disbursement of CPRIT funds is additive to the...

Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dose Pemvidutide was well-tolerated without the need for dose titration No discontinuations due to treatment-emergent adverse events NASH IND has cleared FDA review; 12-week NAFLD study to begin in the near future Altimmune to host a conference call today at 8:30 am ESTGAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. The Phase 1 study was a first-in-human, randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study in overweight and obese volunteers...